Printer Friendly

HOECHST-ROUSSEL PHARMACEUTICALS SETS NEW PRICING POLICY

 SOMERVILLE, N.J., June 22 /PRNewswire/ -- Hoechst-Roussel Pharmaceuticals announced today that it will limit its annualized price increases for prescription drugs to the cumulative forecasted rate of inflation as measured by the Consumer Price Index (CPI). The rate will be calculated and weighted over the entire Hoechst-Roussel product line.
 "Hoechst-Roussel has always had a conservative pricing policy," explains Dr. John K. Herdklotz, Hoechst-Roussel president. "Our announcement today reflects the company's long-time commitment to helping to ensure the affordability of our medicines and our desire to play a positive role in the current national examination of our health- care system."
 Over the 10-year period from 1982 to 1992, the cumulative average price increase for Hoechst-Roussel's medicines was 3.8 percent, below the 5.1 percent cumulative increase in the CPI for the same period. In addition, Hoechst-Roussel in April 1992 froze the price of its anti- hypertensive drug, Altace(TM) (ramipril), until the year 2000.
 Hoechst-Roussel's pricing commitment is contingent on stable market conditions and government policies that encourage company investments in research and development.
 Hoechst-Roussel is a subsidiary of Hoechst Celanese Corporation. Hoechst Celanese is a Fortune 100 company with sales of $7 billion. It is a wholly owned subsidiary of Hoechst AG of Germany with leading positions in chemicals, fibers, advanced materials and technologies and the life sciences.
 -0- 6/22/93
 /CONTACT: Andrea Stine of Hoechst-Roussel Pharmaceuticals, 908-231-3752/


CO: Hoechst-Roussel Pharmaceuticals ST: New Jersey IN: MTC SU:

WB -- NY060 -- 4601 06/22/93 13:23 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 22, 1993
Words:248
Previous Article:HADSON ENERGY RESOURCES CORPORATION ANNOUNCES PRELIMINARY RESULTS OF OFFSHORE OIL TEST
Next Article:STANDARD & POOR'S STOCK PRICE INDEX NOON, TUESDAY, JUNE 22 /PRN/
Topics:


Related Articles
HOECHST-ROUSSEL FORMS DERMATOLOGY DIVISION
BEHRINGWERKE, HOECHST-ROUSSEL COMMENCE ACTION AGAINST IMMUNEX
HOECHST-ROUSSEL PHARMACEUTICALS DONATES MEDICINE TO HELP FLORIDA RECOVERY
ADDITIONAL DATA NEEDED FOR HOECHST-ROUSSEL'S MENTANE, SAYS FDA ADVISORY COMMITTEE
ONCOGENE SCIENCE, INC. AND HOECHST-ROUSSEL ENTER INTO COLLABORATIVE AGREEMENT
COMPANIES ANNOUNCE DEFINITIVE AGREEMENTS FOR HOECHST TO ACQUIRE MARION MERRELL DOW
CHRISTIAN M. ERTLE TO LEAD CORPORATE PHARMACEUTICAL MANUFACTURING FOR HOECHST MARION ROUSSEL
A NEW GLOBAL STRENGTH IN PHARMACEUTICALS: HOECHST MARION ROUSSEL BEGINS TO TAKE SHAPE FOLLOWING AGREEMENT WITH FTC
HOECHST MARION ROUSSEL TO INVEST IN GENOMIC RESEARCH AS A COMPLEMENT TO TRADITIONAL DRUG DISCOVERY EFFORTS
U.S. FDA Clears Indication Television Advertising Hoechst Marion Roussel's Allegra(R) To Debut New Commercial

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters